Study shows ReGen's Colostrinin to have anti-aging, anticancer potential

By E. Janene Geiss

Philadelphia, Sept. 1 - ReGen Therapeutics plc said Friday that an in vitro study has indicated that its compound Colostrinin may have an impact on the aging process and the development of cancer in addition to its known therapeutic benefits for Alzheimer's disease.

Study results show that Colostrinin reduces the spontaneous or induced mutation frequency in the DNA of cells, according to a news release by the London biotechnology company. Because DNA damage is implicated in the general process of aging and the development of cancer, this study suggests Colostrinin may have potential in the prevention of both processes, officials said.

These results were recently published in the Journal of Experimental Therapeutics and Oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.